Lead Product(s) : JR-141
Therapeutic Area : Genetic Disease
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In this study, 50 patients with Hunter syndrome will be treated with JR-141 or the standard treatment for up to 105 weeks under a standard of care controlled, parallel-group trial design.
Product Name : JR-141
Product Type : Antibody
Upfront Cash : Inapplicable
October 02, 2021
Lead Product(s) : JR-141
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : JR-141
Therapeutic Area : Genetic Disease
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JR-141 is a recombinant fusion protein of antibody against the human transferrin receptor and idursulfase, the enzyme missing or malfunctioning in subjects with MPS II.
Product Name : JR-141
Product Type : Antibody
Upfront Cash : Inapplicable
October 02, 2021
Lead Product(s) : JR-141
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : JR-141
Therapeutic Area : Genetic Disease
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
JCR Announces Presentations on JR-141 and JR-162 at the 16th Annual WORLDSymposium 2020
Details : The presentations highlight two candidates from JCR’s development pipeline for lysosomal storage disorders; JR-141 and JR-162.
Product Name : JR-141
Product Type : Antibody
Upfront Cash : Inapplicable
February 13, 2020
Lead Product(s) : JR-141
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable